Apheresis therapy in children: An overview of key technical aspects and a review of experience in pediatric renal disease

Journal of Clinical Apheresis

Volumn 28, Issue 1, 2013, Pages 36-47

  Hunt, Elizabeth A K ^a,b   Jain, Namrata G ^a,b   Somers, Michael J G ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

apheresis medicine; children; plasmapheresis; therapeutic apheresis; therapeutic apheresis academy

Indexed keywords

AGE; ANTICOAGULANT THERAPY; ANTIGLOMERULARBBASEMENT MEMBRANE DISEASE; APHERESIS; AWARENESS; CHILDHOOD DISEASE; CONFERENCE PAPER; DESENSITIZATION; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GRAFT FAILURE; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOADSORPTION; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; NEPHRITIS; PATIENT SAFETY; RARE DISEASE; REPETITION PRIMING; VASCULAR ACCESS;

ADOLESCENT; ANTICOAGULANTS; ANXIETY; BLOOD COMPONENT REMOVAL; BLOOD VOLUME; CATHETERIZATION, CENTRAL VENOUS; CHILD; CITRIC ACID; ERYTHROCYTES; GRAFT REJECTION; HUMANS; HYPOCALCEMIA; IMMUNOSORBENT TECHNIQUES; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; NEPHROLOGY; PEDIATRICS; PLASMA EXCHANGE; SOLUTIONS; VASCULAR ACCESS DEVICES;

EID: 84874083510     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21260     Document Type: Conference Paper

References (95)

1. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH,; Apheresis Applications Committee of the American Society of Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society of Apheresis. J Clin Apheresis 2010; 25: 83-177.
2. Weiss PF, Klink AJ, Friedman DF, Feudtner C,. Pediatric therapeutic plasma exchange indications and patterns of use in US children's hospitals. J Clin Apheresis 2012; 6: 287-294.
3. Kim HC,. Therapeutic pediatric apheresis. J Clin Apheresis 2000; 15: 129-157.
4. Geigy JR,. Scientific tables. In:, Diem K, Lentner C, editors. Documenta Geigy: Scientific Tables, 7th ed. Ardsley, NY: Geigy Pharmaceuticals. 1970.
5. Collins JA,. Hemorrhage, shock, and burns. In:, Petz LD, Swisher SN, editors. Clinical Practice of Blood Transfusion. New York: Churchill Livingston, Inc. 1981. pp 425-453.
6. Kevy SV, Fosburg M,. Therapeutic apheresis in childhood. J Clin Apheresis 1990; 5: 87-90.
7. Thompson L,. Central venous catheters for apheresis access. J Clin Apheresis 1992; 7: 154-157.
8. Krishnamurthy G, Keller MS,. Vascular access in children. Cardiovasc Intervent Radiol 2011; 34: 14-24.
9. Michon B, Moghrabi A, Winikoff R, Barrette S, Bernstein ML, Champagne J, David M, Hume HA, Robitaille N, Belisle A, Champagne MA,. Complications of apheresis in children. Transfusion 2007; 47: 1837-1842.
10. Galacki DM,. An overview of therapeutic apheresis in pediatrics. J Clin Apheresis 1997; 12: 1-3.
11. Kiprov DD, Golden P, Rohe R, Smith S, Hofmann J, Hunnicutt J,. Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures. J Clin Apheresis 2001; 16: 130-133.
12. Howard MA, Williams LA, Terrell DR, Duvall D, Vesely SK, George JN,. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2006; 46: 154-156.
13. North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Annual Transplant Report (Online). 2010. Available at: https://web.emmes.com/study/ped/annlrept/annlrept.html. Accessed on July 31, 2012.
14. Hoyer JR, Vernier RL, Najarian JS, Raij L, Simmons RL, Michael AF,. Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet 1972; 2: 343-348.
15. Tejani A, Stablein DH,. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1992; 2: S258-S263.
16. Baum MA, Stablein DM, Panzarino VM, Tejani A, Harmon WE, Alexander SR,. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int 2001; 59: 328-333.
17. Abbott KC, Sawyers ES, Oliver JD III, Ko CW, Kirk AD, Welch PG, Peters TG, Agodoa LY,. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am J Kidney Dis 2001; 37: 366-373.
18. Schachter AD, Harmon WE,. Single-center analysis of early recurrence of nephrotic syndrome following renal transplantation in children. Pediatr Transplant 2001; 5: 406-409.
19. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F,. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334: 878-883.
20. Artero ML, Sharma R, Savin VJ, Vincenti F,. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994; 23: 574-581.
21. Ohta T, Kawaguchi H, Hattori M, Komatsu Y, Akioka Y, Nagata M, Shiraga H, Ito K, Takahashi K, Ishikawa N, Tanabe K, Yamaguchi Y, Ota K,. Effect of pre- and post-operative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in children. Transplantation 2001; 71: 628-633.
22. Pradhan M, Petro J, Palmer J, Meyers K, Baluarte H,. Early use of plasmapheresis for recurrent post-transplant FSGS. Pediatr Nephrol 2003; 18: 934-938.
23. Gohh RY, Yango AF, Morrissey PE, Monaco AP, Gautam A, Sharma M, McCarthy ET, Savin VJ,. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005; 5: 2907-2912.
24. Garcia CD, Bittencourt VB, Tumelero A, Antonello JS, Malheiros D, Garcia VD,. Plasmapheresis for recurrent posttransplant focal segmental glomerulosclerosis. Transplant Proc 2006; 38: 1904-1905.
25. Fencl F, Simkova E, Vondrak K, Janda J, Chadimova M, Stejskal J, Seeman T,. Recurrence of nephrotic proteinuria in children with focal segmental glomerulosclerosis after renal transplantation treated with plasmapheresis and immunoadsorption: case reports. Transplant Proc 2007; 39: 3488-3490.
26. Fuentes GM, Meseguer CG, Carrion AP, Hijosa MM, Garcia-Pose A, Melgar AA, Torres MN,. Long-term outcome of focal segmental glomerulosclerosis after pediatric renal transplantation. Pediatr Nephrol 2010; 25: 529-534.
27. Sethna C, Benchimol C, Hotchkiss H, Frank R, Infante L, Vento S, Trachtman H,. Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab. J Transplant 2011;2011: 389542.
28. Gonzalez E, Ettenger R, Rianthavorn P, Tsai E, Malekzadeh M,. Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation. Pediatr Transplant 2011; 15: 495-501.
29. Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K,. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003; 42: 1121-1130.
30. Somers MJG, Baum MA,. Pre-transplant conditioning with plasmapheresis and cyclosporine infusion reduces recurrence of focal segmental glomerulosclerosis (fsgs) in children. Pediatr Transplant 2009; 13 (Supp 1): 96.
31. Grisaru S, Yuen GW, Miettunen PM, Hamiwka LA,. Incidence of Wegener's granulomatosis in children. J Rheumatol 2010; 37: 440-442.
32. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012; 2: 233-239.
33. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD,; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 2180-2188.
34. Walsh M, Catapano F, Szpirt W, Thorlund K, Bruchfeld A, Guillevin L, Haubitz M, Merkel PA, Peh CA, Pusey C, Jayne D,. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 2011; 57: 566-574.
35. Szpirt WM, Heaf JG, Petersen J,. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis-a clinical randomized controlled trial. Nephrol Dial Transplant 2011; 26: 206-213.
36. Shimizu M, Sekiguchi T, Kishi N, Goji A, Takahashi T, Kozan H, Sakaguchi Z, Kinoshita Y, Matsuura S, Suga K, Urushihara M, Kondo S, Kagami S, Ohara K,. A case of a 6-year-old girl with anti-neutrophil cytoplasmic autoantibody- negative pauci-immune crescentic glomerulonephritis. Clin Exp Nephrol 2011; 15: 596-601.
37. Akioka Y, Hattori M, Kawaguchi H, Ito K,. A case of chronic relapsing ANCA-associated microscopic polyangiitis successfully treated with plasma exchange. Ther Apher Dial 2004; 8: 223-226.
38. Nash MC, Jones CL, Walker RG, Powell HR,. Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in children. Pediatr Nephrol 1993; 7: 11-14.
39. Walters MD, Savage CO, Dillon MJ, Lockwood CM, Barratt TM,. Antineutrophil cytoplasm antibody in crescentic glomerulonephritis. Arch Dis Child 1988; 63: 814-817.
40. Wright E, Dillon MJ, Tullus K,. Childhood vasculitis and plasma exchange. Eur J Pediatr 2007; 166: 145-151.
41. Siomou E, Tramma D, Bowen C, Milford DV,. ANCA-associated glomerulonephritis/systemic vasculitis in childhood: clinical features-outcome. Pediatr Nephrol 2012; 10: 1911-1920.
42. United States Renal Data System. Atlas of End Stage Renal Disease (ESRD). Chapter 8: Pediatric End Stage Renal Disease (Online). 2011. Available at: http://www.usrds.org/2011/pdf/v2-ch08-11.pdf. Accessed on August 2, 2012.
43. Saus J, Wieslander J, Langeveld JP, Quinones S, Hudson BG,. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem 1988; 263: 13374-13380.
44. Simpson IJ, Doak PB, Williams LC, Blacklock HA, Hill RS, Teague CA, Herdson PB, Wilson CB,. Plasma exchange in Goodpasture's syndrome. Am J Nephrol 1982; 2: 301-311.
45. Johnson JP, Moore J Jr,., Austin HA III, Balow JE, Antonovych TT, Wilson CB., Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 1985; 64: 219-227.
46. Levy JB, Turner AN, Rees AJ, Pusey CD,. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 134: 1033-1042.
47. Dewan D, Gulati S, Sharma RK, Prasad N, Jain M, Gupta A, Kumar A,. Clinical spectrum and outcome of crescentic glomerulonephritis in children in developing countries. Pediatr Nephrol 2008; 23: 389-394.
48. McCarthy LJ, Cotton J, Danielson C, Graves V, Bergstein J,. Goodpasture's syndrome in childhood: treatment with plasmapheresis and immunosuppression. J Clin Apheresis 1994; 9: 116-119.
49. Pusey CD, Lockwood CM, Peters DK,. Plasma exchange and immunosuppressive drugs in the treatment of glomerulonephritis due to antibodies to the glomerular basement membrane. Int J Artif Organs 1983;(Suppl 1): 15-18.
50. Banatvala N, Griffin PM, Greene KD, Barrett TJ, Bibb WF, Green JH, Wells JG,. The United States National prospective hemolytic uremic syndrome study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 2001; 183: 1063-1070.
51. Scheiring J, Andreoli SP, Zimmerhackl LB,. Treatment and outcome of shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008; 23: 1749-1760.
52. Siegler RL, Pavia AT, Christofferson RD, Milligan MK,. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics 1994; 94: 35-40.
53. Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF,. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003; 290: 1360-1370.
54. Zimmerhackl LB, Besbas N, Jungraithmayr T, van de Kar N, Karch H, Karpman D, Landau D, Loirat C, Proesmans W, Prüfer F, Rizzoni G, Taylor MC,; European Study Group for Haemolytic Uraemic Syndromes and Related Disorders. Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost 2006; 32: 113-120.
55. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C,; French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; 18: 2392-2400.
56. Loirat C, Frémeaux-Bacchi V,. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011; 6: 60.
57. Matsukuma E, Gotoh Y, Kuroyanagi Y, Yamada T, Iwasa M, Yamakawa S, Nagai T, Takagi N, Mae H, Iijima K, Bresin E,. A case of atypical hemolytic uremic syndrome due to anti-factor H antibody in a patient presenting with a factor XII deficiency identified two novel mutations. Clin Exp Nephrol 2011; 15: 269-274.
58. Kim JJ, Goodship TH, Tizard J, Inward C,. Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations. Pediatr Nephrol 2011; 26: 2073-2076.
59. Davin JC, Olie KH, Verlaak R, Horuz F, Florquin S, Weening JJ, Groothoff JW, Strain L, Goodship TH,. Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: concordant presentation, discordant response to treatment. Am J Kidney Dis 2006; 47: e27-e30.
60. Filler G, Radhakrishnan S, Strain L, Hill A, Knoll G, Goodship TH,. Challenges in the management of infantile factor H associated hemolytic uremic syndrome. Pediatr Nephrol 2004; 19: 908-911.
61. Stratton JD, Warwicker P,. Successful treatment of factor H-related haemolytic uraemic syndrome. Nephrol Dial Transplant 2002; 17: 684-685.
62. Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, Thomas C, Smith R, Brophy P,. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011; 6: 1488-1494.
63. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB,; European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009; 24: 687-696.
64. Sheth KJ, Gill JC, Hanna J, Leichter HE,. Failure of fresh frozen plasma infusions to alter the course of hemolytic uremic syndrome. Child Nephrol Urol 1988-1989; 9: 38-41.
65. Rizzoni G, Claris-Appiani A, Edefonti A, Facchin P, Franchini F, Gusmano R, Imbasciati E, Pavanello L, Perfumo F, Remuzzi G,. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988; 112: 284-290.
66. Loirat C, Sonsino E, Hinglais N, Jais JP, Landais P, Fermanian J,. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 1988; 2: 279-285.
67. Loos S, Ahlenstiel T, Kranz B, Staude H, Pape L, Härtel C, Vester U, Buchtala L, Benz K, Hoppe B, Beringer O, Krause M, Müller D, Pohl M, Lemke J, Hillebrand G, Kreuzer M, König J, Wigger M, Konrad M, Haffner D, Oh J, Kemper MJ,. An outbreak of shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012; 6: 753-759.
68. Pradhan M, Raffaelli RM, Lind C, Meyers KEC, Kaplan BS, Baluarte HJ, Monos D,. Successful deceased donor renal transplant in a sensitized pediatric recipient with the use of plasmapheresis. Pediatr Transplant 2008; 12: 711-716.
69. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL,. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
70. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC,. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251.
71. Huh KH, Kim BS, Yang J, Ahn J, Kim MG, Park JB, Kim JM, Chung BH, Kim JK, Kong JM,. Kidney transplantation after desensitization in sensitized patients: a Korean National Audit. Int Urol Nephrol 2012; 44: 1549-1557.
72. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE,. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
73. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, Hacen C, Duboust A, Bariety J,. Desensitization and subsequent kidney transplantation of patients using immunoglobulins (IVIg). Am J Transplant 2002; 2: 758-760.
74. Uchida J, Machida Y, Iwai T, Naganuma T, Kitamoto K, Iguchi T, Maeda S, Kamada Y, Kuwabara N, Kim T, Nakatani T,. Desensitization protocol in highly HLA-sensitized and ABO-incompatible high titer kidney transplantation. Transplant Proc 2010; 42: 3998-4002.
75. Jin MK, Cho JH, Kwon O, Hong KD, Choi JY, Yoon SH, Park SH, Yim YL, Kim CD,. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. Transplant Proc 2012; 44: 200-203.
76. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K,. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
77. Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Cendales L, Demetris AJ, Drachenberg CB, Farver CF, Rodriguez ER, Wallace WD, Glotz D,. Banf 2011 Meeting report: a new concepts in antibody-mediated rejection. Banf Meeting Report Writing Committee. Am J Transplant 2012; 12: 563-570.
78. Al-Badr W, Kallogjeri D, Madaraty K, Oliver D, Bastani B, Grossman BJ,. A retrospective review of the outcome of plasma exchange and aggressive medical therapy in antibody mediated rejection of renal allografts: a single center experience. J Clin Apher 2008; 23: 178-182.
79. Brown CM, Abraham KA, O'Kelly P, Conlon PJ, Walshe JJ,. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transplant Proc 2009; 41: 3690-3692.
80. Slatinska J, Honsova E, Burgelova M, Slavcev A, Viklicky O,. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience. Ther Apher Dial 2009; 13: 108-112.
81. Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF,. Pathologic features of acute renal allograft rejection associated with donor-specific antibody, analysis using the Banff grading schema. Transplantation 1996; 61: 1586-1592.
82. Kaposztas Z, Podder H, Mauiyyedi S, Illoh O, Kerman R, Reyes M, Pollard V, Kahan B,. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23: 63-73.
83. Abraham KA, Brown C, Conlon PJ, Donohoe J, Hickey DP, O'Neill D, Keogan MT, Dorman AM, Walshe J,. Plasmapheresis as rescue therapy in accelerated acute humoral rejection. J Clin Apher 2003; 18: 103-110.
84. Pascual M, Saidman S, Tolkoff-Rubin N, Williams WW, Mauiyyedi S, Duan JM, Farrell ML, Colvin RB, Cosimi AB, Delmonico FL,. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66: 1460-1464.
85. Ibernõn M, Gil-Vernet S, Carrera M, Serõn D, Moreso F, Bestard O, Cruzado JM, Grinyõ JM,. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant Proc 2005; 37: 3743-3745.
86. White NB, Greenstein SM, Cantafio AW, Schechner R, Glicklich D, McDonough P, Pullman J, Mohandas K, Boctor F, Uehlinger J, Tellis V,. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004; 78: 772-774.
87. Lehrich RW, Rocha PN, Reinsmoen N, Greenberg A, Butterly DW, Howell DN, Smith SR,. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. Hum Immunol 2005; 66: 350-358.
88. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C,. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099-1107.
89. Furth S, Neu AM, Hart J, Zachary A, Colombani P, Fivush BA,. Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: a case report. Pediatr Transplant 1999; 3: 146-149.
90. Kranz B, Kelsch R, Kuwertz-Bröking E, Bröcker V, Wolters HH, Konrad M,. Acute antibody-mediated rejection in paediatric renal transplant recipients. Pediatr Nephrol 2011; 26: 1149-1156.
91. Morath C, Becker LE, Leo A, Beimier J, Klein K, Seckinger J, Kihm LP, Schemmer P, Macher-Goeppinger S, Wahrmann M, Bohmig GA, Opelz G, Susal C, Zeier M, Schwenger V,. ABO-incompatible kidney transplantation enabled by non-antigen specific immunoadsorption. Transplantation 2012; 93: 827-834.
92. Bartel G, Schwaiger E, Bohmig GA,. Prevention and treatment of allo-antibody-mediated kidney transplant rejection. Transpl Int 2011; 24: 1142-1155.
93. Higgins RM, Bevan DJ, Carey BS, Lea CK, Fallon M, Buhler R, Vaughan RW, O'Donnell PJ, Snowden SA, Beewick M, Hendry BM,. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996; 348: 1208-1211.
94. Bartel G, Wahrmann M, Regele H, Kikic Z, Fischer G, Muhlbacher F, Bohmig GA,. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant 2010; 10: 2033-2042.
95. Bohmig GA, Wahrmann M, Regele H, Exner M, Robl B, Derfler K, Soliman T, Bauer P, Mullner M, Druml W,. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized control trial. Am J Transplant 2007; 7: 117-121.